Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
Recruiting · NCT06396416 · Interventional (participants receive a specific treatment) · Lead sponsor: Western University, Canada
View the official record on ClinicalTrials.gov →Interventions studied
SemaglutideVirtual Weight Management Coaching
What this trial is about
OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Adults aged 18 years or older
- BMI; 35 kg/m\^2
- 10% risk of ESKD requiring renal replacement therapy over 2 years or receiving dialysis
Exclusion criteria
- Known contraindication to a GLP-1RA (pancreatitis, personal or family history of medullary thyroid cancer, hypersensitivity)
- Type 1 diabetes
- No access to semaglutide via drug coverage
- Pregnant, breastfeeding or planning to become pregnant
- Currently in a GLP-1RA or GLP-1RA/GIP study or planning to be in one
Where it is running
1 location listed.
- London Health Sciences Centre - London, Ontario, Canada